Discontinued fluoroquinolones

Ashwin Swaminathan

doi:10.1201/9781315152110

Discontinued fluoroquinolones

Ashwin Swaminathan^*

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Temafloxacin, trovafloxacin (CP-99,219), grepafloxacin (OPC- 17116), and clinafloxacin (AM-1091, CI-960, PD127391) are newer generation fluoroquinolones that share a broad spectrum of antimicrobial activity against Enterobacteriacieae, Gram-positive bacteria (including Streptococcus pneumoniae and Staphylococcus aureus), clinically significant anaerobes, and “atypical” respiratory pathogens. Grepafloxacin and trovafloxacin are generally less active against Pseudomonas spp. than ciprofloxacin, sitafloxacin, and clinafloxacin. These agents were withdrawn from the market (temafloxacin, trovafloxacin, and grepafloxacin) or from pre-marketing development (clinafloxacin) in the 1990s following serious antibiotic-related adverse events that came to light during pre- and post-marketing surveillance.

Original language	English
Title of host publication	Kucers the Use of Antibiotics
Subtitle of host publication	A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
Publisher	CRC Press
Pages	2309-2318
Number of pages	10
ISBN (Electronic)	9781498747967
ISBN (Print)	9781498747950
DOIs	https://doi.org/10.1201/9781315152110
Publication status	Published - 1 Jan 2017

Access to Document

10.1201/9781315152110

Cite this

@inbook{472d9be3e9064f549d16e1e2796a709d,

title = "Discontinued fluoroquinolones",

abstract = "Temafloxacin, trovafloxacin (CP-99,219), grepafloxacin (OPC- 17116), and clinafloxacin (AM-1091, CI-960, PD127391) are newer generation fluoroquinolones that share a broad spectrum of antimicrobial activity against Enterobacteriacieae, Gram-positive bacteria (including Streptococcus pneumoniae and Staphylococcus aureus), clinically significant anaerobes, and “atypical” respiratory pathogens. Grepafloxacin and trovafloxacin are generally less active against Pseudomonas spp. than ciprofloxacin, sitafloxacin, and clinafloxacin. These agents were withdrawn from the market (temafloxacin, trovafloxacin, and grepafloxacin) or from pre-marketing development (clinafloxacin) in the 1990s following serious antibiotic-related adverse events that came to light during pre- and post-marketing surveillance.",

author = "Ashwin Swaminathan",

note = "Publisher Copyright: {\textcopyright} 2018 by Taylor & Francis Group, LLC.",

year = "2017",

month = jan,

day = "1",

doi = "10.1201/9781315152110",

language = "English",

isbn = "9781498747950",

pages = "2309--2318",

booktitle = "Kucers the Use of Antibiotics",

publisher = "CRC Press",

}

TY - CHAP

T1 - Discontinued fluoroquinolones

AU - Swaminathan, Ashwin

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Temafloxacin, trovafloxacin (CP-99,219), grepafloxacin (OPC- 17116), and clinafloxacin (AM-1091, CI-960, PD127391) are newer generation fluoroquinolones that share a broad spectrum of antimicrobial activity against Enterobacteriacieae, Gram-positive bacteria (including Streptococcus pneumoniae and Staphylococcus aureus), clinically significant anaerobes, and “atypical” respiratory pathogens. Grepafloxacin and trovafloxacin are generally less active against Pseudomonas spp. than ciprofloxacin, sitafloxacin, and clinafloxacin. These agents were withdrawn from the market (temafloxacin, trovafloxacin, and grepafloxacin) or from pre-marketing development (clinafloxacin) in the 1990s following serious antibiotic-related adverse events that came to light during pre- and post-marketing surveillance.

AB - Temafloxacin, trovafloxacin (CP-99,219), grepafloxacin (OPC- 17116), and clinafloxacin (AM-1091, CI-960, PD127391) are newer generation fluoroquinolones that share a broad spectrum of antimicrobial activity against Enterobacteriacieae, Gram-positive bacteria (including Streptococcus pneumoniae and Staphylococcus aureus), clinically significant anaerobes, and “atypical” respiratory pathogens. Grepafloxacin and trovafloxacin are generally less active against Pseudomonas spp. than ciprofloxacin, sitafloxacin, and clinafloxacin. These agents were withdrawn from the market (temafloxacin, trovafloxacin, and grepafloxacin) or from pre-marketing development (clinafloxacin) in the 1990s following serious antibiotic-related adverse events that came to light during pre- and post-marketing surveillance.

UR - http://www.scopus.com/inward/record.url?scp=85056681370&partnerID=8YFLogxK

U2 - 10.1201/9781315152110

DO - 10.1201/9781315152110

M3 - Chapter

SN - 9781498747950

SP - 2309

EP - 2318

BT - Kucers the Use of Antibiotics

PB - CRC Press

ER -

Discontinued fluoroquinolones

Abstract

Access to Document

Other files and links

Fingerprint

Cite this